Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St., Jackson 1115, Boston, MA, 02114, USA.
Department of Orthopedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Cancer Chemother Pharmacol. 2016 Feb;77(2):349-56. doi: 10.1007/s00280-015-2944-z. Epub 2015 Dec 23.
Multidrug resistance (MDR) is a major obstacle to the successful treatment of osteosarcoma with chemotherapy. Effectiveness of cancer therapy correlates with the ability to induce a p53-dependent apoptotic response. p53 is a tumor suppressor gene that is mutated in 22 % of osteosarcomas. While impaired p53 has been implicated in the oncogenesis of osteosarcoma, it is unclear whether overexpression of wild-type p53 can increase chemosensitivity in MDR osteosarcoma cells.
We transfected a plasmid encoding the wild-type p53 gene to MDR osteosarcoma cell lines, which have different p53 statuses, U-2OSR2 with wild-type p53 (Wt-p53) and KHOSR2 with mutant p53 (Mt-p53), and determined the effect of p53 overexpression on chemosensitivities.
Both of the U-2OSR2 and KHOSR2 cell lines displayed similar trends in p53-induced drug sensitivities. However, it seems that the impact of p53 overexpression is different based on the differential intrinsic p53 status in these cell lines. In the KHOSR2 cell line (Mt-p53), overexpression of p53 up-regulates the expression of pro-apoptotic protein p21 and Bax, while in the U-2OSR2 cell line (Wt-p53), overexpression of p53 down-regulates IGF-1r expression significantly.
These results demonstrated that transfection of wild-type p53 increases chemosensitivity either through inhibiting IGF-1r or through increasing the expression of pro-apoptotic proteins p21 and Bax in human MDR osteosarcoma cell lines.
多药耐药(MDR)是骨肉瘤化疗成功的主要障碍。癌症治疗的效果与诱导 p53 依赖性凋亡反应的能力相关。p53 是一种肿瘤抑制基因,在 22%的骨肉瘤中发生突变。虽然功能失调的 p53 被认为与骨肉瘤的发生有关,但尚不清楚野生型 p53 的过表达是否能增加 MDR 骨肉瘤细胞的化疗敏感性。
我们将编码野生型 p53 基因的质粒转染到具有不同 p53 状态的 MDR 骨肉瘤细胞系中,包括具有野生型 p53(Wt-p53)的 U-2OSR2 和具有突变型 p53(Mt-p53)的 KHOSR2,并确定 p53 过表达对化疗敏感性的影响。
U-2OSR2 和 KHOSR2 细胞系的 p53 诱导药物敏感性均显示出相似的趋势。然而,p53 过表达的影响似乎因这些细胞系中内在 p53 状态的差异而有所不同。在 KHOSR2 细胞系(Mt-p53)中,p53 的过表达上调了促凋亡蛋白 p21 和 Bax 的表达,而在 U-2OSR2 细胞系(Wt-p53)中,p53 的过表达显著下调了 IGF-1r 的表达。
这些结果表明,在人 MDR 骨肉瘤细胞系中,转染野生型 p53 可通过抑制 IGF-1r 或通过增加促凋亡蛋白 p21 和 Bax 的表达来增加化疗敏感性。